Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $315,091.02 in Stock

Key Points

• Agios Pharmaceuticals insider Theodore James Jr. Washburn sold 8,546 shares for a total of $315,091.02, representing a 90.78% decrease in his position, leaving him with only 868 shares.
• The company's recent earnings report showed a loss of $1.93 earnings per share, missing estimates, while revenue was reported at $12.50 million, beating expectations.
• Brokerage firms have issued mixed ratings on Agios, with a consensus target price of $56.00, as analysts maintain a moderate buy rating amidst a backdrop of decreased price objectives from some firms.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Theodore James Jr. Washburn sold 8,546 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $36.87, for a total value of $315,091.02. Following the completion of the transaction, the insider directly owned 868 shares of the company's stock, valued at approximately $32,003.16. The trade was a 90.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded down $0.26 during trading on Tuesday, hitting $36.15. The stock had a trading volume of 616,336 shares, compared to its average volume of 722,992. The firm has a market cap of $2.10 billion, a P/E ratio of 3.29 and a beta of 0.87. The business has a fifty day moving average of $37.65 and a two-hundred day moving average of $33.21. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $39,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at $40,000. CWM LLC raised its position in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 320 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages recently issued reports on AGIO. HC Wainwright reissued a "buy" rating and issued a $56.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Bank of America reduced their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Scotiabank dropped their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research report on Monday, July 28th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.